Abstract:We have ported and optimized the graphics processing unit (GPU)-accelerated QUICK and AMBER-based ab initio quantum mechanics/molecular mechanics (QM/MM) implementation on AMD GPUs. This encompasses the entire Fock matrix build and force calculation in QUICK including one-electron integrals, twoelectron repulsion integrals, exchange-correlation quadrature, and linear algebra operations. General performance improvements to the QUICK GPU code are also presented. Benchmarks carried out on NVIDIA V100 and AMD MI10… Show more
“…As modern architectures make extensive use of heterogeneous nodes that combine multicore CPUs with GPUs, ,, achieving exascale will require coupling GPU-ready MM and QM software able to scale on many (≈10 2|3 ) such nodes. While a plethora of classical MD codes already exist that fully exploit GPUs, − including GROMACS used in MiMiC, full implementation for these architectures is still an ongoing process for DFT codes, ,,,, except for the TeraChem proprietary software. , This is arguably the main reason why serious endeavors to port first principle QM/MM MD interfaces to GPUs are appearing only now in the literature. , …”
Section: Discussionmentioning
confidence: 99%
“…56,57 This is arguably the main reason why serious endeavors to port first principle QM/MM MD interfaces to GPUs are appearing only now in the literature. 119,120 Strong scaling on heterogeneous nodes is actually the major challenge for molecular simulation. In force field based MD simulations, this is related to the relatively fixed size of the biological systems of interest 71 and the intrinsic seriality of the time evolution integration algorithms.…”
The initial phases of drug discovery – in silico drug design – could benefit from first
principle Quantum
Mechanics/Molecular Mechanics (QM/MM) molecular dynamics (MD) simulations
in explicit solvent, yet many applications are currently limited by
the short time scales that this approach can cover. Developing scalable
first principle QM/MM MD interfaces fully exploiting current exascale
machines – so far an unmet and crucial goal – will help
overcome this problem, opening the way to the study of the thermodynamics
and kinetics of ligand binding to protein with first principle accuracy.
Here, taking two relevant case studies involving the interactions
of ligands with rather large enzymes, we showcase the use of our recently
developed massively scalable Multiscale Modeling in Computational
Chemistry (MiMiC) QM/MM framework (currently using DFT to describe
the QM region) to investigate reactions and ligand binding in enzymes
of pharmacological relevance. We also demonstrate for the first time
strong scaling of MiMiC-QM/MM MD simulations with parallel efficiency
of ∼70% up to >80,000 cores. Thus, among many others, the
MiMiC
interface represents a promising candidate toward exascale applications
by combining machine learning with statistical mechanics based algorithms
tailored for exascale supercomputers.
“…As modern architectures make extensive use of heterogeneous nodes that combine multicore CPUs with GPUs, ,, achieving exascale will require coupling GPU-ready MM and QM software able to scale on many (≈10 2|3 ) such nodes. While a plethora of classical MD codes already exist that fully exploit GPUs, − including GROMACS used in MiMiC, full implementation for these architectures is still an ongoing process for DFT codes, ,,,, except for the TeraChem proprietary software. , This is arguably the main reason why serious endeavors to port first principle QM/MM MD interfaces to GPUs are appearing only now in the literature. , …”
Section: Discussionmentioning
confidence: 99%
“…56,57 This is arguably the main reason why serious endeavors to port first principle QM/MM MD interfaces to GPUs are appearing only now in the literature. 119,120 Strong scaling on heterogeneous nodes is actually the major challenge for molecular simulation. In force field based MD simulations, this is related to the relatively fixed size of the biological systems of interest 71 and the intrinsic seriality of the time evolution integration algorithms.…”
The initial phases of drug discovery – in silico drug design – could benefit from first
principle Quantum
Mechanics/Molecular Mechanics (QM/MM) molecular dynamics (MD) simulations
in explicit solvent, yet many applications are currently limited by
the short time scales that this approach can cover. Developing scalable
first principle QM/MM MD interfaces fully exploiting current exascale
machines – so far an unmet and crucial goal – will help
overcome this problem, opening the way to the study of the thermodynamics
and kinetics of ligand binding to protein with first principle accuracy.
Here, taking two relevant case studies involving the interactions
of ligands with rather large enzymes, we showcase the use of our recently
developed massively scalable Multiscale Modeling in Computational
Chemistry (MiMiC) QM/MM framework (currently using DFT to describe
the QM region) to investigate reactions and ligand binding in enzymes
of pharmacological relevance. We also demonstrate for the first time
strong scaling of MiMiC-QM/MM MD simulations with parallel efficiency
of ∼70% up to >80,000 cores. Thus, among many others, the
MiMiC
interface represents a promising candidate toward exascale applications
by combining machine learning with statistical mechanics based algorithms
tailored for exascale supercomputers.
“…As modern architectures make extensive use of heterogeneous nodes that combine mul-ticore CPUs with GPUs, 55,110,111 achieving exascale will require coupling GPU-ready MM and QM software able to scale on many (≈ 10 2|3 ) such nodes. While a plethora of classical MD codes already exist that fully exploit GPUs, [112][113][114][115] including GROMACS 71 used in MiMiC, full implementation for these architectures is still an ongoing process for DFT codes, 61,63,65,66,116 except for the TeraChem proprietary software. 56,57 This is arguably the main reason why serious endeavours to port first principle QM/MM MD interfaces to GPUs are appearing only now in the literature.…”
The initial phases of drug discovery - in silico drug design - could benefit from first principle Quantum Mechanics / Molecular Mechanics (QM/MM) molecular dynamics (MD) simulations in explicit solvent, yet many applications are currently limited by the short time scales that this approach can cover. Developing scalable first principle QM/MM MD interfaces fully exploiting current exascale machines - so far an unmet and crucial goal - will help overcome this problem, opening the way to the study of the thermodynamics and kinetics of ligand binding to protein with first principle accuracy. Here, taking two relevant case studies involving the interactions of ligands with rather large enzymes, we showcase the use of our recently developed massively scalable MiMiC QM/MM framework (currently using DFT to describe the QM region) to investigate reactions and ligand binding in enzymes of pharmacological relevance. We also demonstrate for the first time strong scaling of MiMiC QM/MM MD simulations with parallel efficiency above 70\% with over 40,000 cores. Thus, among many others, the MiMiC interface represents a promising candidate towards exascale applications by combining machine learning with statistical mechanics based algorithms tailored for exascale supercomputers.
“…Amber has had a long tradition of QM/MM methods and implementations, with the most recent additions being the QUICK/sander QM/MM implementation in AmberTools23. ,− QUICK/sander has been extensively updated, and its performance has been significantly improved. QUICK, as distributed with AmberTools23, can also be used as a standalone QM program for single point calculations or geometry optimizations.…”
AmberTools is a free and open-source collection of programs used to set up, run, and analyze molecular simulations. The newer features contained within AmberTools23 are briefly described in this Application note.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.